Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Study summary

This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBosutinib and Pemetrexed

The study team can explain what participation involves.

Who it may be forMesothelioma · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 14, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Nagla Abdel Karim

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Nagla Abdel Karim
Interventions being studied: Drug: Bosutinib; Drug: Pemetrexed

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Mesothelioma→

Disease setting

Metastatic or stage IV→

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Pathologically or cytologically proven advanced, metastatic non-squamous non-small cell lung cancer, pleural malignant mesothelioma, bladder or urethral cancer, ovarian cancer, primary peritoneal cancer, thymoma and thymic cancer and uterine cervical cancer.
Measurable disease
Life expectancy of greater than 3 months.
Ability to take folic acid, vitamin B12, and dexamethasone according to protocol.

Reasons someone may not be able to joinExclusion criteria

\- Untreated or symptomatic brain metastases.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Augusta University Georgia Cancer CenterAugusta, Georgia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 14, 2022. Always confirm current availability with the study team.

View original record ↗